hESC-Derived Dendritic Cells for Standardized CD4+ T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and expanding antigen-specific CD4+ T cell populations are limited by variability in the preparation of primary dendritic cells and the heterogeneity of HLA-DR receptors, making it difficult to develop universal probes for autoimmune disorders.
Innovation Solution
The use of human embryonic stem cell-derived dendritic cells, which are differentiated into mature professional antigen-presenting cells capable of presenting specific peptide antigens, allowing for the standardized expansion and characterization of CD4+ T cell responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary dendritic cells are used for antigen presentation, then T cell stimulation can be achieved, but variability in preparation and HLA-DR heterogeneity reduce reliability and standardization
Solution Approach 1:
The patent changes the source parameter of dendritic cells from primary human cells to human embryonic stem cell-derived cells. This parameter change eliminates HLA-DR heterogeneity and enables standardized antigen presentation while maintaining the essential function of T cell stimulation. The hESC-derived dendritic cells provide a uniform, reproducible platform for immunological studies and therapeutic applications.
2Reliability
If standardized antigen presentation is implemented, then diagnostic and therapeutic reliability improves, but the complexity of stem cell differentiation protocols increases
Solution Approach 1:
The patent performs preliminary differentiation of human embryonic stem cells into dendritic cells in advance, creating a standardized cell product that can be stored and used repeatedly. This preliminary action eliminates the need for repeated complex differentiation protocols when conducting T cell studies, thereby improving reliability while managing complexity through upfront preparation.
Solution Approach 2:
The patent creates copies of dendritic cells from a single hESC source through controlled differentiation. These copied cells provide consistent antigen presentation capabilities without requiring repeated access to primary dendritic cell sources, standardizing the platform for multiple experiments and applications.
3Productivity
If ex vivo expansion of antigen-specific T cells is performed, then therapeutic cell populations can be generated, but variability in APC preparation affects expansion efficiency
Solution Approach 1:
The patent changes the source parameter of antigen-presenting cells from variable primary cells to standardized hESC-derived dendritic cells. This parameter change ensures consistent antigen presentation and reliable T cell expansion efficiency across different experiments and patients, improving both productivity and reliability of ex vivo T cell therapy manufacturing.
Data Source
Figure 1A~1D
Figure 1E~1I
Figure 1J~1M
AI summary
The invention relates to methods, peptides, nucleic acids and cells for use in isolating and expanding human T cell populations in an antigen-specific manner for immunodiagnostic or therapeutic purposes. The invention also relates to professional antigen presenting cells derived from pluripotent human stem cells, and to customizable antigen presentation by the antigen presenting cells.